Eloxx Pharmaceuticals, Inc. ELOX
NASDAQ
| 06/30/2026 | 06/30/2023 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | -24.63% | -9.67% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 17.26% | -24.49% | |||
| Operating Income | -17.26% | 24.49% | |||
| Income Before Tax | -19.93% | 30.32% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -19.93% | 30.32% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -19.93% | 30.32% | |||
| EBIT | -17.26% | 24.49% | |||
| EBITDA | -- | 24.51% | |||
| EPS Basic | 22.58% | 31.77% | |||
| Normalized Basic EPS | 23.73% | 27.01% | |||
| EPS Diluted | 22.58% | 31.77% | |||
| Normalized Diluted EPS | 23.73% | 27.01% | |||
| Average Basic Shares Outstanding | 54.91% | 2.12% | |||
| Average Diluted Shares Outstanding | 54.91% | 2.12% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||